Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Non-Current Deferred Tax Liability (2016 - 2017)

Lisata Therapeutics filings provide 8 years of Non-Current Deferred Tax Liability readings, the most recent being $1.1 million for Q1 2017.

  • For the quarter ending Q1 2017, Non-Current Deferred Tax Liability rose 13.61% year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Mar 2017, up 13.61%, and an annual FY2016 reading of $1.1 million, up 14.8% over the prior year.
  • Non-Current Deferred Tax Liability hit $1.1 million in Q1 2017 for Lisata Therapeutics, up from $1.1 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $35.5 million in Q4 2013, with the low at $932662.0 in Q4 2015.
  • Median Non-Current Deferred Tax Liability over the past 5 years was $4.1 million (2013), compared with a mean of $9.5 million.
  • The sharpest move saw Non-Current Deferred Tax Liability soared 369.11% in 2014, then crashed 94.87% in 2015.
  • Year by year, Non-Current Deferred Tax Liability stood at $35.5 million in 2013, then crashed by 48.87% to $18.2 million in 2014, then tumbled by 94.87% to $932662.0 in 2015, then grew by 14.8% to $1.1 million in 2016, then grew by 4.63% to $1.1 million in 2017.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $1.1 million, $1.1 million, and $1.1 million for Q1 2017, Q4 2016, and Q3 2016 respectively.